Hypnosis & Direct Autonomic Experience Influence on Chronic Symptoms

Status Not yet recruiting

Clinical Trial Summary

Study will look at a limited number of participants with various chronic symptoms. Investigating a new and novel form of hypnosis application called "Direct Autonomic Experience (DAX)" which is using combination of visualization, metaphor, post-hypnotic suggestion and anchoring.

Purpose is to confirm that DAX generally appears to impact SUDS value and subjects report observed level of effect on short and longer term measurements.

Most significantly, testing that DAX technique/action is reusable later if the measured SUDS value returns or increases.

Clinical Trial Description

Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms One common characteristic of many chronic conditions is the neurology/ biology/ symptomology may change slightly or signficantly over time. So an initial process/plan that worked well for affecting a SUDS discomfort level, may no longer work or work as well.

DAX is designed to be adaptive such that as matters that affected the initial SUDS conditions may have changed, shifted, grown or otherwise be different.

(Examples are increased lesions with MS). Where initial patterns were created with a certain set of neural condition and pathways. But now days/weeks later, with new pathways created, can a previously installed DAX pattern adjust and shift to accommodate the new neural patterns based on participants willingness and self-instruction, or does it require professional adjustment.

Example participant given strong post-hypnotic suggestions/anchor/etc to squeeze right hand in certain way to bring relief to leg discomfort. Initial testing shows working. Now time has shifted, maybe new pathways or other chronic conditions have changed. Can the DAX processes the participant has been taught handle these changes or does it require a professional to re-apply/boost or incorporate new details to get significant changes to reported SUDS discomfort values. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04303143
Study type	Observational [Patient Registry]
Source	Inner Group Inc.
Contact	Martin Vendemia, BCH, MNLP
Phone	410-709-7449
Email	Martin@innergroupinc.com
Status	Not yet recruiting
Phase
Start date	March 2021
Completion date	July 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05528666` - Risk Perception in Multiple Sclerosis
Completed	`NCT03608527` - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis	N/A
Recruiting	`NCT05532943` - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Phase 1/Phase 2
Completed	`NCT02486640` - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed	`NCT01324232` - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis	Phase 2
Completed	`NCT04546698` - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting	`NCT04380220` - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed	`NCT02835677` - Integrating Caregiver Support Into MS Care	N/A
Completed	`NCT03686826` - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting	`NCT05964829` - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis	N/A
Withdrawn	`NCT06021561` - Orofacial Pain in Multiple Sclerosis
Completed	`NCT03653585` - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting	`NCT04798651` - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis	N/A
Active, not recruiting	`NCT05054140` - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis	Phase 2
Completed	`NCT05447143` - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis	N/A
Recruiting	`NCT06195644` - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients	Phase 1
Completed	`NCT04147052` - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis	N/A
Completed	`NCT03594357` - Cognitive Functions in Patients With Multiple Sclerosis
Completed	`NCT03591809` - Combined Exercise Training in Patients With Multiple Sclerosis	N/A
Completed	`NCT02845635` - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms — HDAX1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms